Abeona Therapeutics Inc. (ABEO) Sees Strong Trading Volume on Analyst Upgrade
Abeona Therapeutics Inc. (NASDAQ:ABEO) saw unusually-strong trading volume on Wednesday after Maxim Group raised their price target on the stock to $8.00. Approximately 693,645 shares changed hands during trading, an increase of 221% from the previous session’s volume of 216,338 shares.The stock last traded at $6.50 and had previously closed at $5.78.
ABEO has been the topic of a number of other research reports. Cantor Fitzgerald started coverage on Abeona Therapeutics in a research report on Wednesday, September 7th. They set a “buy” rating and a $21.00 price objective on the stock. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. FBR & Co reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Friday, August 26th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research note on Sunday, August 21st. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Abeona Therapeutics currently has an average rating of “Buy” and an average price target of $12.80.
A number of large investors have recently bought and sold shares of the company. Royce & Associates LP boosted its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares during the last quarter. Sabby Management LLC boosted its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares during the last quarter. 19.95% of the stock is owned by institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/abeona-therapeutics-inc-abeo-sees-strong-trading-volume-on-analyst-upgrade.html
The firm’s 50 day moving average price is $4.38 and its 200 day moving average price is $3.11. The stock’s market capitalization is $220.39 million.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. Equities analysts predict that Abeona Therapeutics Inc. will post ($0.73) EPS for the current fiscal year.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.